GA Depot (Long-acting IM Injection of Glatiramer Acetate) Presents Improved Safety and Tolerability Features: Results from a Multinational, Double-blind, Placebo-controlled Phase III Study in Subjects with Relapsing Forms of Multiple Sclerosis (P8-6.018)

Ehud Marom,Nadav Kimelman,Aaron Miller,Laura Popper,Uri Danon,Hadar Kolb,Shai Rubnov

doi:10.1212/wnl.0000000000205369

GA Depot (Long-acting IM Injection of Glatiramer Acetate) Presents Improved Safety and Tolerability Features: Results from a Multinational, Double-blind, Placebo-controlled Phase III Study in Subjects with Relapsing Forms of Multiple Sclerosis (P8-6.018)

Ehud Marom, Nadav Kimelman + Show 5 more

https://doi.org/10.1212/wnl.0000000000205369

Copy DOI

Journal: Neurology

Publication Date: Apr 9, 2024

#Long-acting Injection #Injection Of Acetate + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

GA Depot (Long-acting IM Injection of Glatiramer Acetate) Presents Improved Safety and Tolerability Features: Results from a Multinational, Double-blind, Placebo-controlled Phase III Study in Subjects with Relapsing Forms of Multiple Sclerosis (P8-6.018)

Full Text